| 000 | 01800 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515224748.0 | ||
| 264 | 0 | _c20110524 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1433-8726 | ||
| 024 | 7 |
_a10.1007/s00345-010-0570-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSiebels, M | |
| 245 | 0 | 0 |
_aA clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. _h[electronic resource] |
| 260 |
_bWorld journal of urology _cFeb 2011 |
||
| 300 |
_a121-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRohrmann, K | |
| 700 | 1 | _aOberneder, R | |
| 700 | 1 | _aStahler, M | |
| 700 | 1 | _aHaseke, N | |
| 700 | 1 | _aBeck, J | |
| 700 | 1 | _aHofmann, R | |
| 700 | 1 | _aKindler, M | |
| 700 | 1 | _aKloepfer, P | |
| 700 | 1 | _aStief, C | |
| 773 | 0 |
_tWorld journal of urology _gvol. 29 _gno. 1 _gp. 121-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00345-010-0570-2 _zAvailable from publisher's website |
| 999 |
_c19864438 _d19864438 |
||